- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01807611
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation With a TLI Based Conditioning Regimen in Patients With Hematologic Malignancies
In this study, participants with high-risk hematologic malignancies undergoing hematopoietic cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA) matched related/sibling donor (MSD) or matched unrelated donor (MUD) identified, will receive a haploidentical donor HCT with additional natural killer (NK) cells.
The investigators anticipate enrollment of 75 donors and 75 recipients.
PRIMARY OBJECTIVE:
- To estimate the rate of successful engraftment at day +42 post-transplant in patients who receive haploidentical donor stem cell plus NK cell transplantation with TLI based conditioning regimen for high risk hematologic malignancy.
SECONDARY OBJECTIVES:
- Estimate the incidence of malignant relapse, event-free survival, and overall survival at one-year post-transplantation.
- Estimate incidence and severity of acute and chronic (GVHD).
- Estimate the rate of transplant related mortality (TRM) in the first 100 days after transplantation.
Study Overview
Status
Detailed Description
Donors will undergo G-CSF mobilization of peripheral blood stem cells (PBSC) prior to undergoing two apheresis collections of hematopoietic progenitor cells (HPC,A) and one apheresis collection of therapeutic cell product of purified natural killer cells (TC-NK).
The HPC products will be T-cell depleted (TCD) using the investigational CliniMACS device. CD34+ enrichment and CD45RA depletion will be utilized on sequential HPC grafts.
Participants will undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, granulocyte colony stimulating factor (G-CSF), thiotepa, and melphalan. This is followed by infusions of donor cells that have been prepared using the CliniMACS system: HPC,A (CD34+ selected), HPC,A (CD45RA depleted), and TC-NK.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children'S Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria - Transplant Recipients:
- Age less than or equal to 21 years.
- Does not have a suitable MSD or volunteer MUD available in the necessary time for stem cell donation.
- Has a suitable single haplotype matched (≥ 3 of 6) and family member donor.
- High risk hematologic malignancy.
- If prior CNS leukemia, it must be treated and in CNS CR
- Does not have any other active malignancy other than the one for which this HCT is indicated.
- No prior allogeneic HCT, and no autologous HCT within the previous 12 months.
- Patient must fulfill pre-transplant evaluation
Inclusion Criteria - Haploidentical Donor:
- At least single haplotype matched (≥ 3 of 6) family member
- At least 18 years of age.
- HIV negative.
- Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female).
- Not breast feeding.
- Regarding eligibility, is identified as either: (1) Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR (2) Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Transplant Recipients
Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna. Cells for infusion are prepared using the CliniMACS System. |
The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS).
The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g.
apheresis products).
These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Other Names:
Given IV.
Other Names:
Participants receive total lymphoid irradiation over four doses.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
Participants receive infusions of TC-NK.
Participants receive G-CSF subcutaneously or intravenously. Donors receive G-CSF subcutaneously during cell mobilization.
Other Names:
Mesna is generally dosed at approximately 25% of the cyclophosphamide dose.
It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
Other Names:
Given intravenously or orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Transplant Recipients With Successful Engraftment
Time Frame: 42 days post engraftment
|
Neutrophil engraftment will be determined using the parameters put forth by the Center for International Blood and Marrow Registry.
Assessments will be made upon review of daily complete blood count and serial chimerism studies.
Successful engraftment for the purposes of this objective will be patients who do not experience graft failure.
|
42 days post engraftment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Transplant Recipients With Malignant Relapse
Time Frame: One-year post-transplantation
|
Bone marrow studies for disease status evaluation will be performed at 1-year post-transplant.
Testing will include a research evaluation for minimal residual disease.
|
One-year post-transplantation
|
Event-free Survival
Time Frame: One year post-transplantation
|
The one-year event free survival is defined by the patient who has neither experienced relapse nor death within one year after post transplantation.
And the rate is calculated by computing the ratio between total number of one year event free survival patients and the total number of patients.
|
One year post-transplantation
|
Overall Survival
Time Frame: one year post-transplantation
|
The one-year survival is defined by the patient who has not died within one year after post transplantation.
And the rate is calculated by computing the ratio between total number of one year survival patients and the total number of patients.
|
one year post-transplantation
|
Number of Transplant Recipients With Acute and/or Chronic Graft Versus Host Disease (GVHD)
Time Frame: 100 days post-transplant for acute GVHD; one year post-transplant for chronic GVHD .
|
Acute and chronic graft-vs.-host
disease will be evaluated using the standard grading criteria.
The estimate will be the number of recipients who experienced GVHD divided by the total number of patients considered in this group.
|
100 days post-transplant for acute GVHD; one year post-transplant for chronic GVHD .
|
Number of Transplant Recipients With Transplant-related Mortality (TRM)
Time Frame: In the first 100 days after transplantation
|
Estimate the proportion of patients died within 100 days after the transplantation who has not experienced a relapse.
The estimate will be the number of TRM divides the total number of patients considered in this group.
|
In the first 100 days after transplantation
|
Severity of Acute Graft Versus Host Disease (aGVHD)
Time Frame: 100 days post-transplant for acute GVHD.
|
Ongoing assessment of toxicity will be done using the NCI CTCAE version 3.0.
Acute and chronic graft-vs.-host
disease will be evaluated using the standard grading criteria.
The severity of acute GvHD and chronic GvHD will be described.
The analysis for this objective will be performed when the last evaluable participant has been followed for 100 days post transplant.
Acute GvHD is graded from 1-4 with 4 being the worst outcome.
|
100 days post-transplant for acute GVHD.
|
Severity of Chronic Graft Versus Host Disease (cGVHD)
Time Frame: 1 year post-transplant for chronic GVHD .
|
Ongoing assessment of toxicity will be done using the NCI CTCAE version 3.0.
Acute and chronic graft-vs.-host
disease will be evaluated using the standard grading criteria.
The severity of acute GvHD and chronic GvHD will be described.
The analysis for this objective will be performed when the last evaluable participant has been followed for 1 year post-transplant.
Chronic GvHD is graded as "mild", "moderate" or "severe" with "severe" being the worst outcome.
|
1 year post-transplant for chronic GVHD .
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Hematologic Diseases
- Hematologic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Anti-Bacterial Agents
- Adjuvants, Immunologic
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cyclophosphamide
- Lenograstim
- Melphalan
- Fludarabine
- Mycophenolic Acid
- Thiotepa
- Mechlorethamine
Other Study ID Numbers
- HAPNK1
- NCI-2013-00609 (REGISTRY: NCI Clinical Trial Registration Program)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
Ruijin HospitalThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsNot yet recruitingLymphoma | Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma | Intravascular Large B-Cell Lymphoma | Extranodal Lymphoma | NK/T-Cell Lymphoma, Nasal and Nasal-TypeChina
Clinical Trials on CliniMACS
-
Neena Kapoor, M.D.Not yet recruitingAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Hematologic Malignancy | Graft Vs Host Disease | Graft-versus-host-disease | Non-hematologic Malignancy
-
Christopher DvorakRecruitingGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
-
University of Colorado, DenverNot yet recruitingHematologic Malignancy | Pediatric Patients | Other Hematologic ConditionUnited States
-
Wake Forest University Health SciencesTerminatedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Immune Deficiency | Lymphomas | Bone Marrow Failure | Osteopetrosis | HemoglobinopathyUnited States
-
Ginna LaportTerminatedAcute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors | Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase | Myelodysplastic Syndrome (MDS) - High and Intermediate Risk | Non-Hodgkin's Lymphoma (NHL) | Chronic Lymphocytic Leukemia...United States
-
Joanne Kurtzberg, MDDuke University; Miltenyi Biotec, Inc.AvailableHematologic Malignancies | Immune Deficiencies | Inborn Errors of Metabolism DisordersUnited States
-
Joseph AntinMiltenyi Biomedicine GmbHNo longer availableGraft Failure | Delayed Graft Function | Graft-Versus-Host Disease(GVHD) | Anemia Due to Disturbance of Proliferation and/or Differentiation of Hematopoietic Stem CellsUnited States
-
Dana-Farber Cancer InstituteMiltenyi Biomedicine GmbHCompletedHematologic MalignanciesUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...RecruitingHaploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion (HAPLOTAB)Myelodysplastic Syndromes | Primary Immunodeficiency Diseases | Hemoglobinopathies | Chronic Myeloid Leukemia | Cytopenia | Severe Aplastic Anemia | Bone Marrow Failure Syndrome | Acute Myeloid Leukemia in Remission | Hemophagocytic Lymphohistiocytoses | Acute Lymphoblastic Leukemia in Remission | Severe...United States
-
Children's Hospital of PhiladelphiaRecruitingParoxysmal Nocturnal Hemoglobinuria | Acquired Aplastic Anemia | Inherited Bone Marrow Failure SyndromesUnited States